VCP
OYST

Verus Capital Partners’s Oyster Point Pharma, Inc. Common Stock OYST Stock Holding History

Verus Capital Partners’s Portfolio OYST Stock Details OYST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-300
Closed -$7K – 1626
2019
Q4 		$7K Buy
+300
New +$5.27K ﹤0.01% 1248

Other funds holding OYST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KXA
KPCB XIV Associates Menlo Park, California $42.8M AUM 16.52% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Verus Capital Partners's OYST Position: Q1 2020 in Review

Verus Capital Partners sold out of Oyster Point Pharma, Inc. Common Stock (OYST) in Q1 2020, closing a stake of 300 shares — an estimated $7K sold.

Verus Capital Partners first reported a position in OYST in Q4 2019 and held it in 1 quarter. The position peaked at $7K in Q4 2019. 43 funds tracked by Wall St. Rank hold OYST as of Q1 2020.

  • Verus Capital Partners reported no remaining Oyster Point Pharma, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Verus Capital Partners sold 300 Oyster Point Pharma, Inc. Common Stock shares in Q1 2020, an estimated $7K.
  • Verus Capital Partners first reported a position in Oyster Point Pharma, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Verus Capital Partners's Oyster Point Pharma, Inc. Common Stock position peaked at $7K in Q4 2019.
  • 43 funds tracked by Wall St. Rank held Oyster Point Pharma, Inc. Common Stock as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.